Navigation Links
Actinomyces viscosus

Multiporator / Electroporator 2510 Transformation Protocol Protocol No. 4308 915.501 04/2002 Microorganism Actinomyces viscosus Cell type Bacteria, gram negative Molecules injected Plasmid DNA (in 1 mM Tris-HCl-0.1 mM EDTA (pH 8.0)) Growth medium Lactobacillus carrying medium (LCM) with 20 mM DL-threonine Washing solution Sterile, distilled water; sterile 10% glycerol Electroporation solution Sterile, 10% glycerol Outgrowth medium Complex medium (CAM) Cuvette 2 mm gap width Reference Yeung, M. K. and Kozelsky, C. S. 1994 Journal of Bacteriology 176. No. 13 4173-4176 Making electrocompetent cells:
  1. Grow a 500 ml cell culture in the early exponential phase until an O.D.600 of 0.2 is reached. Chill on ice for 1.5 h.
  2. 2. Harvest by centrifugation.
  3. Wash extensively first with a large volume of ice-cold sterile distilled water and then with sterile 10% glycerol.
  4. Resuspend in 10% glycerol to a final volume of 2 ml. Store in aliquots at 80 C.
Electroporation of cells:
  1. Thaw bacterial suspensions on ice. Add up to 5 l (100 ng) plasmid DNA to 100 l (5 x 108) of electrocompetent cells. Homogenize by gently mixing with pipette several times. Transfer mixture into prechilled cuvette.
  2. Wipe moisture from the cuvette and insert the cuvette into the device.
  3. Electroporation:

    Mode Prokaryotes O Voltage (V) 2,500 V Time constant (T) 5 ms
  4. Dilute cells with 1 ml of CAM and incubate for 2 h at 37 C.
  5. Plate onto selective brain heart infusion agar plates; incubate at 37 C for up to 5 days.

Expected results:

Transformation efficiency up to 2.9 x 107 transformants/g of DNA.


'"/>

Source:


Page: All 1 2

Related biology technology :

1. Actinomyces viscosus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, ... Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ... to deliver therapeutic levels of olanzapine for a period of 3 months., “We are ...
(Date:2/24/2017)... , Feb. 24, 2017 Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... the deadline to participate in its previously announced ... consisting of shares of common stock and Series ... holders of listed warrants. As ...
(Date:2/24/2017)... Feb. 24, 2017 Symic Bio, a biopharmaceutical ... new category of therapeutics, announced today the completion of ... peripheral artery disease. The trial will evaluate the safety ... in the reduction of restenosis following angioplasty. ... milestone for SB-030," said Nathan Bachtell , M.D., ...
(Date:2/24/2017)... KONG, Feb. 24, 2017 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its unaudited financial results for the third ... ended December 31, 2016. Third Quarter of ... third quarter of fiscal 2017 increased by 18.6% to ...
Breaking Biology Technology:
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market Intelligence ... Biometrics and Digital Identity".  Acuity characterizes 2017 as ... when increased adoption reflects a new understanding of ... "Biometrics and digital identity are often perceived ... Maxine Most , Principal of Acuity Market intelligence. ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
Breaking Biology News(10 mins):